FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:2807-2809 December 29, 2005 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article Related Article by The Breast International Group (BIG) 1-98 Collaborative Group PubMed Citation

Great strides have been made in the diagnosis and treatment of early-stage breast cancer, thanks to advances in molecular medicine, interdisciplinary treatment, and rapid electronic communication. Hormonal therapy, the first and most successful targeted therapy for breast cancer, has saved many thousands of lives. Moreover, screening and adjuvant (postoperative) therapy have increased survival among women with breast cancer.^1,2 The improvement in survival can be attributed to both adjuvant tamoxifen therapy and adjuvant chemotherapy and has been found in all subgroups of patients regardless of the presence or absence of tumor cells in draining lymph nodes, including women who are premenopausal, . . . [Full Text of this Article]

Source Information

From the Breast Cancer Section, Center for Cancer Research, National Cancer Institute, Bethesda, Md.

This article has been cited by other articles:

• Barone, I., Cui, Y., Herynk, M. H., Corona-Rodriguez, A., Giordano, C., Selever, J., Beyer, A., Ando, S., Fuqua, S. A.W. (2009). Expression of the K303R Estrogen Receptor-{alpha} Breast Cancer Mutation Induces Resistance to an Aromatase Inhibitor via Addiction to the PI3K/Akt Kinase Pathway. Cancer Res. 69: 4724-4732 [Abstract] [Full Text]  
• Soldin, S. J., Soldin, O. P. (2009). Steroid Hormone Analysis by Tandem Mass Spectrometry. Clin. Chem. 55: 1061-1066 [Abstract] [Full Text]  
• Sabnis, G. J., Macedo, L. F., Goloubeva, O., Schayowitz, A., Brodie, A. M.H. (2008). Stopping Treatment Can Reverse Acquired Resistance to Letrozole. Cancer Res. 68: 4518-4524 [Abstract] [Full Text]  
• Lin, L., Ercan, O., Raza, J., Burren, C. P., Creighton, S. M., Auchus, R. J., Dattani, M. T., Achermann, J. C. (2007). Variable Phenotypes Associated with Aromatase (CYP19) Insufficiency in Humans. J. Clin. Endocrinol. Metab. 92: 982-990 [Abstract] [Full Text]  
• Erban, J. K., Lau, J. (2006). On the Toxicity of Chemotherapy for Breast Cancer--the Need for Vigilance.. JNCI J Natl Cancer Inst 98: 1096-1097 [Full Text]  
• Diani-Moore, S., Papachristou, F., Labitzke, E., Rifkind, A. B. (2006). INDUCTION OF CYP1A AND CYP2-MEDIATED ARACHIDONIC ACID EPOXYGENATION AND SUPPRESSION OF 20-HYDROXYEICOSATETRAENOIC ACID BY IMIDAZOLE DERIVATIVES INCLUDING THE AROMATASE INHIBITOR VOROZOLE. Drug Metab. Dispos. 34: 1376-1385 [Abstract] [Full Text]  
• (2006). Letrozole vs. Tamoxifen for Early Breast Cancer. JWatch Women's Health 2006: 2-2 [Full Text]